Targovax receives approval in Australia to conduct a clinical trial withTG02 - an immunotheraphy treatment targeting RAS mutations
(Thomson Reuters ONE) -
Oslo 2 June 2016: Targovax receives approval to conduct a study with TG02 and
pembrolizumab, a checkpoint inhibitor, in patients with locally recurrent RAS
mutated rectal cancer.
TGO2 is a cancer vaccine containing a mixture of 8 synthetic peptides
representing fragments of the most common RAS mutations seen in colorectal
cancer disease.
Mutations in RAS, a protein regulating cell growth, is seen in about 50% of
patients with colorectal cancer and 20-30% of all cancers. It is associated with
a lack of response to chemotherapy and poor prognosis. Previous and ongoing
clinical studies have shown that TG peptides are able to induce RAS mutation
specific immune responses. Targovax is the only research organization with RAS
mutated specific vaccines at clinical development stage. This will be the first
study with TG02 in humans and 20 patients will be included at Australian sites.
The study will assess safety and immune activation, both at lesional level and
in peripheral blood. One cohort will only receive TG02 and another cohort will
receive TG02 in combination with pembrolizumab, a PD-1 receptor inhibitor.
"We have already shown in other indications that TG peptides can induce specific
immune responses and that these are associated with clinical benefits. However,
this study will take us one step further in assessing immune activation at tumor
level. It will also give us an indication on how our immune therapy may be
enhanced when combining with a check point inhibitor" says Magnus Jaderberg, CMO
at Targovax.
For further information, please contact:
Gunnar Gårdemyr, CEO
Phone: +46 73 083 77 79
Email: ggardemyr(at)targovax.com
Øystein Soug, CFO
Phone: +47 906 56 525
Email: oystein.soug(at)targovax.com
Arming the patient's immune system to fight cancer
Targovax is a clinical stage immuno-oncology company developing targeted
immunotherapy treatments for cancer patients. Targovax has a broad and
diversified immune therapy portfolio and aims to become a world leader in its
area. The company is currently developing two complementary and highly targeted
approaches in immuno-oncology.
ONCOS - 102 is a virus-based immunotherapy platform based on engineered
oncolytic viruses armed with potent immune-stimulating transgenes targeting
solid tumors. This treatment is designed to reactivate the immune system's
capacity to recognize and attack cancer cells.
TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the
difficult to treat RAS mutations found in more than 85% of pancreatic cancers,
50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards
demonstrating that TG vaccines will prolong time to cancer progression and
increase survival.
These product candidates will be developed in combination with multiple
treatments, including checkpoint inhibitors in several cancer indications.
Targovax also has a number of other cancer immune therapy candidates in the
early stages of development.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
[HUG#2017396]
Unternehmensinformation / Kurzprofil:
Datum: 02.06.2016 - 08:00 Uhr
Sprache: Deutsch
News-ID 475245
Anzahl Zeichen: 3914
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 220 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax receives approval in Australia to conduct a clinical trial withTG02 - an immunotheraphy treatment targeting RAS mutations"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
